Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 20.28 0.17 (0.85%) Market Cap: 1.72 Bil Enterprise Value: 1.28 Bil PE Ratio: 0 PB Ratio: 3.50 GF Score: 54/100

Syndax Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit Transcript

Feb 21, 2024 / 07:00PM GMT
Release Date Price: $22.23 (-2.80%)
Unidentified Participant

Hi welcome back everyone to the next session of Citi's 2024 Virtual Oncology Leadership Summit. As a reminder, if you have questions for the company, just e-mail me got a multicity.com, and I will do my best to relay to the management team.

So with that, it's my very great pleasure to welcome the senior leadership of Syndax Pharmaceuticals. I have with me the CEO, Michael Metzger; President and Head of Research and Development, Neil Gallagher; and Anjali Ganguli, the Chief Business Officer. So welcome all of you.

Thank you so much for taking the time out of a very busy time in the company over the recent filing of both of the new applications with the FDA, which we'll get into.

Questions & Answers

Unidentified Participant;Michael Metzger
Syndax

But Michael maybe just to start out, if you could just give us a high level on where you are, what are the lead assets? What are the key catalysts for 2024 I already alluded to two of them and then we can take it from there to dig into the details.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot